Exchange Traded Concepts’s Nektar Therapeutics NKTR Stock Holding History

Exchange Traded Concepts’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-62	Closed	-$17K	–	1227
2021 Q3	$17K	Buy	+62	New	+$14.9K	﹤0.01%	961
2021 Q1	–	Sell	-958	Closed	-$244K	–	1121
2020 Q4	$244K	Buy	958 +44	+5%	+$11.4K	0.01%	629
2020 Q3	$227K	Buy	+914	New	+$287K	0.01%	517

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Exchange Traded Concepts's NKTR Position: Q4 2021 in Review

Exchange Traded Concepts sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 62 shares — an estimated $17K sold.

Exchange Traded Concepts first reported a position in NKTR in Q3 2020 and held it in 3 quarters. The position peaked at $244K in Q4 2020. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

Exchange Traded Concepts reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
Exchange Traded Concepts sold 62 Nektar Therapeutics shares in Q4 2021, an estimated $17K.
Exchange Traded Concepts first reported a position in Nektar Therapeutics in Q3 2020 and held it in 3 quarters.
Exchange Traded Concepts's Nektar Therapeutics position peaked at $244K in Q4 2020.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Exchange Traded Concepts's 13F filing for Q4 2021, filed 13 Jan 2022.